Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751573 | 0.90 | BACE1 (0.34) | BACE1DRD2DRD3 | |
| SCHEMBL665211 | 0.80 | DRD2 (0.33) | BACE1DRD2DRD3 | |
| SCHEMBL4373561 | 0.80 | DRD2 (0.33) | BACE1DRD2DRD3 | |
| SCHEMBL4373562 | 0.79 | BRD4 (0.35) | BACE1DRD2DRD3 | |
| SCHEMBL4382206 | 0.78 | BACE1 (0.33) | BACE1DRD2DRD3 | |
| SCHEMBL4373649 | 0.77 | CARM1 (0.35) | BACE1DRD2DRD3 | |
| SCHEMBL4382210 | 0.77 | LMNA (0.35) | BACE1DRD2DRD3 | |
| SCHEMBL665189 | 0.76 | DRD2 (0.34) | BACE1DRD2DRD3 | |
| SCHEMBL4373653 | 0.76 | CYP2D6 (0.40) | DRD2DRD3 | |
| SCHEMBL666149 | 0.74 | ALDH1A1 (0.35) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | BACE1 3676/4885DRD2 2983/4885DRD3 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.